Search
Harrow Inc
HROWAdd to Watchlist
33.080USD
-0.050-0.15%
Close 09-17 16:00（ET）
1.24BMarket Cap
LossP/E TTM
More Details of Harrow Inc Company
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Harrow Inc Profile
Ticker SymbolHROW
Company nameHarrow Inc
IPO dateFeb 08, 2013
CEOMullery (Frank)
Number of employees382
Security typeOrdinary Share
Fiscal year-endFeb 08
Address1A Burton Hills Blvd
CityNASHVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code37215
Phone16157334731
Websitehttps://www.harrow.com/
Ticker SymbolHROW
IPO dateFeb 08, 2013
CEOMullery (Frank)
Company Executives of Harrow Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
President, Chief Financial Officer, Principal Accounting Officer, Corporate Secretary
814.68K
+0.43%
FAQs
Who are the top five shareholders of Harrow Inc?
The top five shareholders of Harrow Inc are: Mr. Mark L. Baum, J.D.
How many institutions hold shares of Harrow Inc (HROW)?
As of 2026Q1, 418 institutions hold shares of Harrow Inc, with a combined market value of approximately 24.67M, accounting for 66.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 347374.00.